Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Memantine in Alzheimer's disease: Final report; commission A05-19C. July 08, 2009 (IQWiG reports; Volume 59).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Memantine in Alzheimer’s disease: Results of the unpublished studies IE2101 and MEM-MD-22 as well as unpublished responder analyses: working paper. July 01, 2010. (IQWiG reports; Volume 74).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Responder analyses for memantine in Alzheimer´s disease: Rapid Report; commission A10-06. March 28, 2011. (IQWiG reports; Volume 84).
Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS ONE 2015; 10(4): e0123289.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.